Download PDF

1. Company Snapshot

1.a. Company Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms.It operates through three segments: Injectables, Generics, and Branded.


The Injectables segment provides generic injectable products primarily for use in hospitals.The Generics segment offers oral and other non-injectable generic products for the retail market.The Branded segment offers branded generics and in-licensed products to retail and hospital markets.


The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory.It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally.The company was founded in 1978 and is based in London, the United Kingdom.

Show Full description

1.b. Last Insights on HIK

Hikma Pharmaceuticals' recent performance faces challenges due to execution concerns, despite analyst optimism on core strengths. The company's institutional owners hold 59% of the company, implying significant influence. A slight increase in the consensus analyst price target to £25.40 from £25.02 reflects reassessment of growth prospects. Meanwhile, Ritedose's FDA approval for generic Tobramycin Inhalation Solution may pose competitive pressure. With no recent earnings release available, investors monitor Hikma's progress amid evolving narratives and shifting expectations.

1.c. Company Highlights

2. Hikma's Earnings Report: A Strong Foundation for Long-term Growth

Hikma's financial performance was marked by revenues that grew in line with expectations, although EPS came in below estimates at $0.548 relative to expectations of $0.798. The company's EBITDA margins stood at 25%, a testament to its strong track record of growth. Hikma's three divisions - MENA, Rx, and Injectables - are expected to drive growth, with the MENA division growing at a fast rate and achieving good margins, while the Rx division has achieved 20% margins and significant EBITDA.

Publication Date: Mar -02

📋 Highlights
  • Leadership Restructuring:: CEO Said Darwazah's return focuses on empowering employees, accelerating R&D investments (5-6% of sales), and appointing key leaders like Hafrun Fridriksdottir (Global R&D) and Areb Kurdi (acting CFO).
  • Injectables Growth Resumption:: Challenges in 2025-2026 (due to CMO/biosimilar delays) followed by 2027 growth driven by TYZAVAN and new biosimilars; European injectables grew 23% in 2024.
  • CMO Expansion:: Bedford acquisition reengineering (1.5–2 years to operationalize) and GBP 5 billion 2030 revenue target, with CMO revenue contributing 20% by 2030 (currently 10%).
  • Margin Improvements:: Injectables margins shifted from mid-30s to high 20s in 2024; target for mid-30s by 2028, supported by RTU product expansion and operational efficiency.
  • R&D and CapEx Focus:: 5-6% R&D investment aligned with peers, with returns expected in 2027–2029; GBP 250 million buyback plan and GBP 5 billion 2030 revenue target remain intact.

Segment Performance

The injectables business faces challenges in 2025 and 2026 due to reduced CMO, biosimilar, and product launch delays. However, the company expects growth to resume in 2027, driven by products like TYZAVAN, expansion in Europe, and new biosimilars in MENA. The Rx business is doing well, with a 10% revenue contribution from the CMO business this year, expected to grow to 20% by 2030. The base business, including products like Advil and Fluticasone, is stable.

Growth Drivers

Hikma's growth is expected to be driven by its R&D investments, which have increased by 5-6% of group sales, in line with competitors. The company is investing in people, including a new CMO Head, and is reengineering its Bedford site to offer domestic production. The company's injectable margin is expected to improve, with a mid-term target of around 30%. The company's guidance for a strong CMO business in '28 and forward is supported by its growing portfolio and expansion in Europe.

Valuation

Using valuation metrics, Hikma's P/E Ratio of 9.33 and EV/EBITDA of 7.61 suggest that the company's shares are reasonably priced. The company's ROE of 15.83% and ROIC of 10.21% indicate a strong return on equity and invested capital. With a dividend yield of 4.99%, Hikma offers an attractive return for income investors.

Outlook

The company's 2030 revenue target of GBP 5 billion is still achievable, driven by growth in the branded business, Rx, and injectables. Analysts estimate next year's revenue growth at 5.7%, which is in line with Hikma's long-term growth strategy. With a strong foundation in place, Hikma is well-positioned to deliver on its mid-term targets and create long-term value for shareholders.

3. NewsRoom

Card image cap

How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation

Nov -28

Source:

Card image cap

Why The Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Updates

Nov -14

Source:

Card image cap

Health Care Roundup: Market Talk

Nov -06

Source:

Card image cap

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

Oct -30

Source:

Card image cap

How Recent Developments Are Rewriting the Story for Hikma Pharmaceuticals

Oct -30

Source:

Card image cap

FTSE 100 hits another high despite concerns over US government shutdown

Oct -01

Source:

Card image cap

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

Oct -01

Source:

Card image cap

Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company

Sep -19

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.08%)

6. Segments

Injectables

Expected Growth: 5%

Hikma Pharmaceuticals PLC's Injectables segment growth is driven by increasing demand for affordable and accessible healthcare, expansion into emerging markets, and a strong pipeline of generic and branded products. Additionally, strategic partnerships and acquisitions, as well as investments in manufacturing capabilities and quality control, contribute to the segment's growth.

Generics

Expected Growth: 3%

Hikma Pharmaceuticals PLC's generics segment growth is driven by increasing demand for affordable medicines, strategic partnerships, and expansion into emerging markets. Additionally, the company's strong pipeline of products and investments in R&D are expected to contribute to its growth. Furthermore, the rising prevalence of chronic diseases and an aging population are also driving demand for generics.

Branded

Expected Growth: 4%

Hikma Pharmaceuticals PLC's branded segment growth is driven by increasing demand for its specialty products, expansion into new markets, and strategic partnerships. Additionally, the company's focus on R&D and product launches has contributed to its growth. Furthermore, the company's strong presence in the Middle East and North Africa region has also driven growth.

Others

Expected Growth: 2%

Hikma Pharmaceuticals PLC's growth is driven by its strong presence in the MENA region, diversified product portfolio, and strategic acquisitions. The company's focus on generics and injectables, as well as its partnerships with multinational companies, have contributed to its growth. Additionally, Hikma's investment in R&D and its ability to capitalize on industry trends, such as the shift towards value-added medicines, have also supported its growth.

7. Detailed Products

Branded Generics

Hikma's branded generics portfolio includes a range of products that are marketed and sold under their own brand names, often in partnership with pharmaceutical companies.

Injectables

Hikma's injectables portfolio includes a range of products used in hospitals and clinics, including antibiotics, analgesics, and anesthetics.

Generics

Hikma's generics portfolio includes a range of products that are bioequivalent to branded products, but at a lower cost.

APIs (Active Pharmaceutical Ingredients)

Hikma's API portfolio includes a range of active pharmaceutical ingredients used in the manufacture of pharmaceutical products.

R&D Services

Hikma's R&D services include contract research and development services for pharmaceutical companies.

8. Hikma Pharmaceuticals PLC's Porter Forces

Forces Ranking

Threat Of Substitutes

Hikma Pharmaceuticals PLC operates in a highly regulated industry, and the threat of substitutes is moderate due to the presence of alternative treatments and generic drugs.

Bargaining Power Of Customers

The bargaining power of customers is low due to the fragmented nature of the pharmaceutical industry, and the lack of concentration among buyers.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the presence of a few large suppliers of raw materials and the dependence of Hikma Pharmaceuticals PLC on these suppliers.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and the need for significant investment in research and development.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established players in the pharmaceutical industry, and the need for Hikma Pharmaceuticals PLC to compete on price, quality, and innovation.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 35.14%
Debt Cost 6.16%
Equity Weight 64.86%
Equity Cost 6.16%
WACC 6.16%
Leverage 54.19%

11. Quality Control: Hikma Pharmaceuticals PLC passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Ipsen

A-Score: 6.0/10

Value: 4.8

Growth: 6.0

Quality: 7.9

Yield: 1.2

Momentum: 8.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Almirall

A-Score: 5.1/10

Value: 4.3

Growth: 2.2

Quality: 5.0

Yield: 1.9

Momentum: 9.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Hikma Pharmaceuticals

A-Score: 5.0/10

Value: 5.5

Growth: 4.4

Quality: 6.3

Yield: 5.6

Momentum: 2.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Sobi

A-Score: 4.8/10

Value: 2.8

Growth: 7.3

Quality: 5.5

Yield: 0.0

Momentum: 7.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Siegfried Holding

A-Score: 4.3/10

Value: 4.6

Growth: 7.4

Quality: 5.5

Yield: 0.6

Momentum: 0.5

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Alvotech

A-Score: 2.9/10

Value: 6.0

Growth: 5.6

Quality: 5.7

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

12.47$

Current Price

12.47$

Potential

-0.00%

Expected Cash-Flows